Thursday Feb 9 | Contract Pharma Breaking News
Aenova Builds Oral Drug Delivery Operation
SkyePharma PLC has sub-let part of its laboratories in Muttenz, Switzerland to the Aenova Group.
SkyePharma: CEO departure not linked to European Flutiform delays
The resignation of CEO Axel Muller was a mutual decision and not linked to delayed efforts to win European approval for the asthma drug Flutiform says delivery tech firm SkyePharma.
Jan 31st 2012 - Edison Investment Research today published a report on SkyePharma entitled "Two Hurdles To Jump". In summary, the report says: SkyePharma's newly appointed CEO, the former finance chief Peter Grant, should be well placed to negotiate the refinancing of the group's A 83m of convertible bonds.
Grant takes top SkyePharma role
SKYEPHARMA CFO Peter Grant has taken the top role at the drug technology company, after Axel Mueller stepped down to pursue other interests.